This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: June 28

McKesson's Moolah

Thank you, Wall Street Journal, for your detailed reporting on McKesson (MCK - Get Report) CEO John Hammergren's record-setting pension. Try as we might, there was no way we here at the Dumbest Lab could have made those calculations.

We simply can't count that high.

Hammergren, who started at the drug distributor back in 1996 and became co-CEO in 1999, would have pocketed $159 million had he voluntarily retired from the company on March 31, according to the WSJ. The Journal's compensation consultants proclaimed it the largest pension kitty on file for current CEOs, and undoubtedly the biggest retirement plan in corporate history.

Take that, Dick Grasso! You thought your $126 million parting gift from the NYSE was hairy, but Hammergren's deal totally hammers your pissant package.

To be fair, Grasso was a quasi-civil servant who was forced to scratch by on his salary during lean years like 2001 when he pulled in $25.6 million, so he needed the big nest egg.

Not so for Hammergren, who ranks atop Forbes CEO salary list with a six-year average compensation of $50.79 million. Over the past five years, he's been paid $285 million dollars, which makes us think that his pension plan may be a wee bit over the top.

Of course, McKesson investors may argue that their own 401(k) accounts have been sufficiently plumped by the stock's growth during Hammergren's reign. McKesson's stock price has more than tripled in his 14 years atop the company, outperforming the S&P 500 along the way.

That said, the vast majority of that outperformance vs. the index has been since 2006, when the Medicare Prescription Drug, Improvement, and Modernization Act officially kicked in. Familiarly known as the prescription drug act, it expanded coverage nationwide and introduced an entitlement benefit for well-known drugs through tax breaks and subsidies.

It also seems to have given McKesson a sense of entitlement as well. The drug wholesaler paid the federal government $190 million in 2012, and tens of millions more to the states on top of that, to settle lawsuits that it illegally inflated drug prices.

If you look at it that way, Hammergren owes a lot of his success -- and retirement riches -- not just to McKesson's boorish board and cockeyed compensation consultants, but to George W. Bush for signing that act into law. Maybe he should buy one of W's paintings or donate some of his pension pile to his presidential library to show his appreciation.

As for McKesson shareholders, though, maybe they should ask for some of their money back. Or at least press the board for answers as to why Hammergren is seeing all that green that should be going to them.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MW $12.75 -2.52%
EBIX $31.44 0.00%
MCK $150.03 0.00%
P $9.09 0.00%
AAPL $93.70 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs